Celgene Corp - Company Profile
Powered by
All the data and insights you need on Celgene Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Celgene Corp Strategy Report
- Understand Celgene Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Celgene Corp patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
EP4058028A1 | Application | PÄDIATRISCHE FORMULIERUNGEN ZUR BEHANDLUNG VON KREBS | A61K31/53; A61K47/26; A61K47/36; A61K9/2009; A61K9/2013; A61K9/2018; A61K9/2054; A61K9/2059; A61K9/2072; A61K9/2077; A61P35/00; A61P35/02; A61P43/00 | September 21, 2022 |
WO2022192621A1 | Application | METHODS FOR USING A HYPOMETHYLATING AGENT TO TREAT DISEASES AND DISORDERS BASED ON GENE MUTATION PROFILES | A61K31/351; A61K31/401; A61K31/404; A61K31/4184; A61K31/436; A61K31/437; A61K31/44; A61K31/4439; A61K31/444; A61K31/519; A61K31/53; A61K31/553; A61K31/706; A61K31/7076; A61K45/06; A61P35/02 | September 15, 2022 |
AU2018301335B2 | Grant | Antiproliferative compounds and methods of use thereof | A61K2300/00; A61K31/496; A61K31/573; A61K31/69; A61K38/05; A61K45/06; A61P35/00; A61P35/02; C07D401/04 | September 15, 2022 |
EP4054622A1 | Application | VERWENDUNG VON CHIMÄREN ANTI-BCMA-ANTIGEN-REZEPTOREN | A61K2039/5156; A61K2039/5158; A61K35/17; A61K38/177; A61K39/001117; A61K47/6803; A61P35/00; C07K14/7051; C07K16/2878; C07K2319/03; G01N2333/525; G01N2333/5412; G01N2333/70578; G01N2800/52; G01N33/4833; G01N33/57407 | September 14, 2022 |
EP4054578A1 | Application | KOMBINATIONSTHERAPIE MIT 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL) METHYL)-2,2-DIFLUOROACETAMID | A61K31/047; A61K31/454; A61K31/573; A61K31/593; A61K33/06; A61K38/2006; A61K39/3955; A61K45/06; C07K16/245; C07K2317/76 | September 14, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer